Memantine Eg

Memantine, the active ingredient in Memantine Eg, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients. GNH USA supplies Memantine Eg as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine Eg acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease. - Alzheimer’s disease (moderate to severe): helps improve cognition, memory and functional abilities. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression. - Cognitive decline in Alzheimer’s disease: may slow the rate of deterioration.

Memantine may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate head pain. - Constipation: reduced bowel movements. - Confusion: transient disorientation. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin rash with blistering. - Seizures: unexpected convulsive episodes. - Cardiac arrhythmia: irregular heart rhythm. - Hepatic dysfunction: signs of liver injury such as jaundice.

Before initiating therapy, several safety considerations should be reviewed. - Renal impairment: dose may need adjustment based on kidney function. - History of seizures: monitor closely for new seizure activity. - Cardiovascular disease: assess blood pressure and heart rhythm regularly. - Concomitant NMDA antagonists: avoid combined use to prevent additive toxicity. - Pregnancy and breastfeeding: safety unknown; use only if benefit outweighs risk. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Memantine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined NMDA blockade can lead to excessive inhibition. - High‑dose zinc supplements: may alter memantine absorption.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefits. - CNS depressants (e.g., benzodiazepines): may increase sedation. - Diuretics: may affect serum electrolyte balance and memantine levels.